Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06451341 · ClinicalTrials.gov registry record
IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas
A clinical trial of HIV, sponsored by University of Nebraska.
- Recruiting
- Registry status
- 55
- Enrollment target
- 2
- Study locations
NCT06451341: Recruiting study of HIV, sponsored by University of Nebraska.
NCT06451341 is a study of HIV that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 55 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06451341, a study of HIV, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for people who live a significant distance from an HIV provider. The main questions it aims to answer are: * Is CAB+RPV LA feasible and acceptable to patients and staff? * What barriers and supports exist and have the most impact on receiving and providing CAB+RPV LA? * How does CAB+RPV LA affect HIV stigma, treatment satisfaction, medication adherence and viral suppression? People living with HIV who reside outside of the Omaha, Nebraska metro area and are starting CAB+RPV LA as part of regular medical care for HIV will be invited to participate in this study which involves completing questionnaires and an interview over 15 months. Clinic staff who are involved in providing HIV care and CAB+RPV LA will also provide input through questionnaires and an interview.
Primary Outcome
Proportion of patient participants that agree/completely agree (average score of 4 or higher) on the acceptability of CAB+RPV LA implementation on the Acceptability of Intervention Measure (AIM) questionnaire (4-item measure of perceived intervention acceptability measured on a Likert scale (1-Completely Disagree to 5-Completely Agree). Score is calculated mean.
Conditions Studied
Interventions
- BEHAVIORAL Acceptability of Intervention Measure (AIM)
- BEHAVIORAL Intervention Appropriateness Measure (IAM)
- BEHAVIORAL Feasibility of Intervention Measure (FIM)
- BEHAVIORAL HIV Stigma Scale Questionnaire
- BEHAVIORAL HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)
Study Locations (2)
Nebraska
- Nebraska Medicine Grand Island Clinic - Grand Island
- University of Nebraska Specialty Care Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2027-04 |
What NCT06451341 shows while recruiting
NCT06451341 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (87% lower).
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 5 interventions - of which Acceptability of Intervention Measure (AIM) is the first listed.
NCT06451341 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT06451341 about?
NCT06451341 is a clinical study titled "IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas". The goal of this implementation science study is to learn about the experience of receiving and providing cabotegravir + rilpivirine long-acting (CAB+RPV LA) injections as treatment for human immunodeficiency virus (HIV) for people who live a significant distance from an HIV provider. The main quest...
What is the current status of trial NCT06451341?
This trial is currently recruiting. The enrollment target is 55 participants. The study started on 2024-07-01. Estimated completion is 2027-04.
What conditions does trial NCT06451341 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT06451341?
The interventions under investigation include: Acceptability of Intervention Measure (AIM) (BEHAVIORAL), Intervention Appropriateness Measure (IAM) (BEHAVIORAL), Feasibility of Intervention Measure (FIM) (BEHAVIORAL), HIV Stigma Scale Questionnaire (BEHAVIORAL), HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06451341?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06451341 being conducted?
This trial has 2 study locations across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06451341's enrollment target sits among peer trials
55 209th of 303 higher than 92 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI